Data / Drug companies / Sandoz Inc
Sandoz Inc: 58 products in the FDA NDC directory, labeler code 61314
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sandoz Inc (labeler code 61314) lists 58 products in the FDA National Drug Code Directory, covering 35 finished drugs by generic name. By type: 58 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 26, 2026.
The request: Watch Sandoz Inc (FDA labeler code 61314): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 61314
- Products in commercial distribution
- 58
- Packages
- 98
- Finished drugs by generic name
- 35
- Prescription products
- 58
- Over the counter products
- 0
- Flagged as original packager
- 51 of 51 products that carry the flag
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- December 15, 1994
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 24 | 41.4% |
| Biologics (BLA) | 22 | 37.9% |
| Authorized generics (NDA) | 9 | 15.5% |
| New drug applications (NDA) | 3 | 5.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 58 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Adalimumab-adaz | 10 | 2 |
| Timolol maleate | 4 | 20 |
| Ustekinumab-ttwe | 3 | 3 |
| Pilocarpine hydrochloride | 3 | 14 |
| Neomycin sulfate, polymyxin b sulfate and hydrocortisone | 3 | 8 |
| Denosumab | 2 | 5 |
| Tropicamide | 2 | 5 |
| Ranibizumab-eqrn | 2 | 2 |
| Brimonidine tartrate | 2 | 15 |
| Filgrastim-sndz | 2 | 1 |
| Polymyxin b sulfate and trimethoprim | 1 | 6 |
| Neomycin and polymyxin b sulfates and dexamethasone | 1 | 5 |
| Prednisolone acetate | 1 | 10 |
| Pegfilgrastim-bmez | 1 | 1 |
| Diclofenac sodium | 1 | 109 |
| Dorzolamide hydrochloride | 1 | 11 |
| Cromolyn sodium | 1 | 11 |
| Cyclopentolate hydrochloride | 1 | 3 |
| Neomycin sulfate, polymyxin b sulfate and dexamethasone | 1 | 11 |
| Trifluridine | 1 | 1 |
| Ketorolac tromethamine | 1 | 69 |
| Latanoprost | 1 | 15 |
| Betaxolol hydrochloride | 1 | 3 |
| Tobramycin and dexamethasone | 1 | 14 |
| Dorzolamide hydrochloride and timolol maleate | 1 | 11 |
| Carteolol hydrochloride | 1 | 1 |
| Gentamicin sulfate | 1 | 20 |
| Tobramycin | 1 | 41 |
| Proparacaine hydrochloride | 1 | 10 |
| Ciprofloxacin hydrochloride | 1 | 36 |
| Aflibercept | 1 | 2 |
| Natalizumab-sztn | 1 | 1 |
| Azelastine hydrochloride | 1 | 17 |
| Apraclonidine | 1 | 1 |
| Gatifloxacin | 1 | 3 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution | 16 | 27.6% |
| Injection, solution | 16 | 27.6% |
| Solution/ drops | 12 | 20.7% |
| Injection | 4 | 6.9% |
| Suspension | 3 | 5.2% |
| Kit | 2 | 3.4% |
| Suspension/ drops | 2 | 3.4% |
| Solution, gel forming / drops | 2 | 3.4% |
| Ointment | 1 | 1.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Enzeevu | 61314-504 | Injection, solution | Biologics (BLA) | October 26, 2026 |
| Tyruko | 61314-543 | Injection | Biologics (BLA) | November 17, 2025 |
| Jubbonti | 61314-240 | Injection | Biologics (BLA) | June 2, 2025 |
| Wyost | 61314-228 | Injection | Biologics (BLA) | June 2, 2025 |
| Adalimumab | 61314-391 | Injection, solution | Biologics (BLA) | March 26, 2025 |
| Pyzchiva | 61314-654 | Injection, solution | Biologics (BLA) | February 22, 2025 |
| Pyzchiva | 61314-652 | Injection, solution | Biologics (BLA) | February 22, 2025 |
| Pyzchiva | 61314-651 | Injection, solution | Biologics (BLA) | February 22, 2025 |
| Adalimumab | 61314-325 | Injection, solution | Biologics (BLA) | January 6, 2025 |
| Cimerli | 61314-625 | Injection, solution | Biologics (BLA) | December 12, 2024 |
| Cimerli | 61314-624 | Injection, solution | Biologics (BLA) | December 12, 2024 |
| Adalimumab | 61314-332 | Injection, solution | Biologics (BLA) | December 2, 2024 |
| Hyrimoz | 61314-531 | Kit | Biologics (BLA) | July 1, 2023 |
| Hyrimoz | 61314-517 | Kit | Biologics (BLA) | July 1, 2023 |
| Hyrimoz | 61314-509 | Injection, solution | Biologics (BLA) | July 1, 2023 |
| Hyrimoz | 61314-476 | Injection, solution | Biologics (BLA) | July 1, 2023 |
| Hyrimoz | 61314-473 | Injection, solution | Biologics (BLA) | July 1, 2023 |
| Hyrimoz | 61314-454 | Injection, solution | Biologics (BLA) | July 1, 2023 |
| Adalimumab | 61314-327 | Injection, solution | Biologics (BLA) | July 1, 2023 |
| Ziextenzo | 61314-866 | Injection | Biologics (BLA) | November 4, 2019 |
| Gatifloxacin | 61314-672 | Solution/ drops | Generic drugs (ANDA) | October 3, 2016 |
| Zarxio | 61314-326 | Injection, solution | Biologics (BLA) | March 6, 2015 |
| Zarxio | 61314-318 | Injection, solution | Biologics (BLA) | March 6, 2015 |
| Azelastine Hydrochloride | 61314-308 | Solution/ drops | Generic drugs (ANDA) | March 21, 2013 |
| Pilocarpine Hydrochloride | 61314-206 | Solution/ drops | Authorized generics (NDA) | September 30, 2011 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.